Friday 6 November 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue: +16.7%
EPS: +747.6%
Free cash flow: −4.76%
Total debt: −2.66%

Quarter to September 2026, against a year earlier

156.74 0.08 +0.05%

Follow ALNY

Alert me

Market cap: $21.0B
P/E: 7.9×
Fwd P/E: 13.5×
Dividend yield: —
F-score: 6/9
Altman Z: 7.30
Beneish M: −1.95
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alnylam Pharmaceuticals, Inc. (ALNY) revenue by segment, product and region

Revenue by product or service $m

Line	FY2022	FY2021
ONPATTRO	558 53.75%	475 56.23%
GIVLAARI	173 16.69%	128 15.14%
Net revenues from collaborations	135 13.00%	181 21.43%
AMVUTTRA	94 9.04%	0 0.00%
OXLUMO	70 6.73%	60 7.06%
Royalty revenue	8 0.79%	1 0.14%
Net product revenues	894	662
Revenue	1,037	844

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Alnylam Pharmaceuticals, Inc. (ALNY) revenue by segment, product and region

Revenue by product or service $m

Stockrow Weekly